Fertility warning
This medicine may affect fertility.
Leaflet PEMETREXED TEVA 25mg / ml concentrate for solution for infusion
- Product code:
- W64094001
- Quantity:
- 1
- Indicated for:
- non-small cell lung cancer
- Route of administration:
- infusion
- Substance:
- pemetrexeda (antimetabolite antineoplastic)
- ATC
- L01BA04 — Antineoplastic and immunomodulating agents | Antimetabolites | Folic acid analogues
Precautions:
Dose adjustment in hepatic impairment
Dose adjustment may be needed in liver disease.
Cytotoxic / special handling
Handle with special care.
Contraception required
Effective contraception is required during treatment.
Contraindicated during breastfeeding
Do not use this medicine while breastfeeding.
Contraindicated during pregnancy
Do not use this medicine during pregnancy.
Hepatotoxicity
This medicine may affect the liver.
Major drug interactions
This medicine may have important interactions with other medicines.
Myelosuppression / agranulocytosis
This medicine may lower blood cell counts.
Additional monitoring
This medicine is subject to additional monitoring.
Requires periodic laboratory tests
Periodic laboratory tests may be required during treatment.
Severe skin reactions
Stop taking the medicine and seek urgent medical help if a severe rash occurs.
Pemetrexed is a chemotherapy agent used in the treatment of lung cancer and malignant pleural mesothelioma. It works by inhibiting enzymes involved in DNA and RNA synthesis, thereby preventing tumor cell growth.
The medication is administered intravenously, as directed by a doctor, usually once every three weeks. It is important for patients to follow the treatment regimen and take folic acid and vitamin B12 supplements to reduce the risk of side effects.
Patients should be aware of potential side effects, such as fatigue, nausea, or decreased blood cell counts. It is important to inform the doctor of any unusual symptoms.
Common side effects include fatigue, nausea, and anemia. In rare cases, severe reactions such as hematologic toxicity or allergic reactions may occur. Patients should be informed of these risks before use.
The medication is administered intravenously, as directed by a doctor, usually once every three weeks. It is important for patients to follow the treatment regimen and take folic acid and vitamin B12 supplements to reduce the risk of side effects.
Patients should be aware of potential side effects, such as fatigue, nausea, or decreased blood cell counts. It is important to inform the doctor of any unusual symptoms.
Common side effects include fatigue, nausea, and anemia. In rare cases, severe reactions such as hematologic toxicity or allergic reactions may occur. Patients should be informed of these risks before use.
General data about PEMETREXED TEVA 25mg / ml
- Substance:
- pemetrexeda
- Date of latest medicines list:
- 01-02-2018
- Product code:
- W64094001
- Concentration:
- 25mg / ml
- Pharmaceutical form:
- concentrate for solution for infusion
- Quantity:
- 1
- Product type:
- Generic medicine
- Prescription status:
- P-RF — Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.
Pharmaceutical forms available for pemetrexeda
Concentrations available for pemetrexeda
- 1000mg
- 100mg
- 10mg/ml
- 25mg/ml
- 500mg